Dextrothyroxine
Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.
![]() | |
| Clinical data | |
|---|---|
| Trade names | Choloxin |
| Other names | D-3,5,3',5'-tetraiodothyronine |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.094 |
| Chemical and physical data | |
| Formula | C15H11I4NO4 |
| Molar mass | 776.87 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
See also
References
- Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–481. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
- Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology. 9 (1): 90–96. PMID 9440092.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.
